Oncorus, a Phase 1 biotech developing oncolytic virus therapies for solid tumors, raised $87 million by offering 5.8 million shares at $15, within the range of $14 to $16.
Oncorus plans to list on the Nasdaq under the symbol ONCR. Jefferies, Evercore ISI and Piper Sandler acted as joint bookrunners on the deal.
